Study finds patient assistance program data advances drug safety
AI-translated from the Chinese original · editorially reviewed
In today's era of exploding healthcare data, adverse event (AE) reporting both challenges drug safety assessment and drives its progress. According to the latest research by Jeremy Jokinen's team, data sources such as patient support/assistance programs (PSPs/PAPs), market research programs (MRPs), and social media hold significant value for collecting and analyzing drug safety data. The study found that the drug safety data provided by PSPs is more valuable and usable than that from other sources.
Data sources and drug safety
As the pharmaceutical industry grows increasingly data-dependent, data collection from PSPs/PAPs, MRPs, and social media has become indispensable. These data have unique value in identifying potential drug risks and adverse reactions, but they also raise challenges of data completeness and reliability.
Jeremy Jokinen's research team used three approaches to assess how different data sources affect drug safety labeling. First, the team examined label changes triggered by PSPs and found that PSPs/PAPs, through regular contact with healthcare providers, can influence drug safety assessments. MRPs and social media, however, did not lead to any label changes, suggesting their direct contribution to drug safety is limited.
Further analysis using the vigiGrade scoring system showed that traditional PSPs/PAPs performed better on data completeness, while MRPs and social media scored lower, pointing to shortcomings in the data quality and completeness of these platforms.
Industry implications and future directions
Traditional PSPs/PAPs, with their structured interaction models and deep engagement with healthcare professionals, have proven to have a significant impact on drug safety monitoring. By contrast, while MRPs and social media contribute little to a deeper understanding of drug safety profiles, their broad user bases and data collection capabilities give them the potential to become more influential data sources in the future. The industry therefore needs to develop more advanced data analysis tools and methods to improve the data quality and usability of these platforms.
The value of drug safety advances driven by PAPs/PSPs
This study highlights the direct impact of PSPs/PAPs in drug safety assessment and contrasts it with the potential roles of market research and social media, demonstrating the real-world value that patient assistance programs bring to advancing drug safety.
Sean Chang, General Manager, PatientsForce, Media-WIND Health Group (MWHG)
References